PBRM1 and nonpapillary renal cell carcinoma: Collectively, these findings suggested that patients with ccRCC, who harbour WT PBRM1 and express PBRM1 mRNA with a high rate of E27 inclusion, show high resistance to PD-1 blockade therapy.